In 10 years, NHGRI hopes to take DNA sequencers from the lab to the clinic, but some companies think 10 years isn't soon enough, says Forbes' Matthew Herper. Illumina's Jay Flatley has already talked about getting regulatory approval "to use his technology for medical purposes," Herper says. And even though regulatory approval — whether of the sequencers themselves or the interpretation of the sequence is unclear — is only the first hurdle.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.